Endometrial Cancer



FREE PREVIEW Login or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.

Am Fam Physician. 1999 Jun 1;59(11):3069-3076.

  See related patient information handout on endometrial cancer, written by the authors of this article.

Endometrial cancer is the fourth most common cancer in women, accounting for approximately 6,000 deaths per year in the United States. It is more common in women who are older, white, affluent, obese and of low parity. Hypertension and diabetes mellitus are also predisposing factors. Because any condition that increases exposure to unopposed estrogen increases the risk of endometrial cancer, tamoxifen therapy, estrogen replacement therapy without progestin and the presence of estrogen-secreting tumors are all risk factors. Smoking and the use of oral contraceptives appear to decrease the risk. Women with an increased risk and those with postmenopausal bleeding should be screened for endometrial cancer. Endometrial sampling is currently the most accurate and widely used screening technique, but ultrasonographic measurement of endometrial thickness and hysteroscopy have also been studied. Patients with endometrial specimens that show atypia have about a 25 percent likelihood of progressing to carcinoma, compared with less than 2 percent in patients without atypia. Endometrial cancer is usually treated surgically, but in patients with appropriate pathologic findings who decline surgical treatment, progestin therapy may be satisfactory.

Uterine cancer, the most common malignant neoplasm of the female genital tract and the fourth most common cancer in women, is currently diagnosed in about 34,000 women each year. In 1997, about 6,000 women in the United States died of this disease.1 It is more frequent in affluent and white women, especially obese, postmenopausal women of low parity.2 Hypertension and diabetes mellitus are also predisposing factors.3 Uterine cancer is most frequently diagnosed in industrialized western nations, with the lowest rates occurring in India and Southeast Asia.2

Advances in the past two decades have expanded our knowledge of endometrial cancer, giving us a better definition of the histologic subtypes and providing us with better screening and surgical tools with which to diagnose and treat this disease.2

Pathogenesis

It was originally hypothesized that endometrial hyperplasia represented a morphologic continuum from benign cystic hyperplasia to atypical complex hyperplasia, which may be the immediate precursor of endometrial carcinoma.2 Several recent studies have suggested that endometrial hyperplasia and endometrial cancer are two different entities, and the distinguishing feature is the presence or absence of cytologic atypia.2 Studies have shown that patients who have endometrial hyperplasia without atypia respond well to progestin therapy and are not at increased risk for cancer; however, patients with cytologic atypia show only a 50 percent response to progestin therapy, and cancer develops in 25 percent of cases.46

Uterine cancer is a general term used to describe many different histopathologic types of tumors found in the uterus. The most common cancer of the uterus is adenocarcinoma. Several other histologic subtypes also occur (Table 1). The less common forms are associated with a lower overall survival rate and a higher risk of metastatic disease at the time of surgical staging.2 Patients with serous (also known as papillary serous) and clear cell carcinomas tend to be older than those with other types (mean age: 66 versus 59 years) and are more likely to have abnormal cervical cytology.7 Serous carcinoma invades the myometrium and lymph-vascular spaces early and has been shown to metastasize without deep myometrial invasion.2

TABLE 1

Classification of Endometrial Carcinoma

Adenocarcinoma

Adenoacanthoma

Adenosquamous

Serous (papillary serous)

Mucinous

Clear cell

Squamous cell

Mixed

Undifferentiated


Information from Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326.

TABLE 1   Classification of Endometrial Carcinoma

View Table

TABLE 1

Classification of Endometrial Carcinoma

Adenocarcinoma

Adenoacanthoma

Adenosquamous

Serous (papillary serous)

Mucinous

Clear cell

Squamous cell

Mixed

Undifferentiated


Information from Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326.

Risk Factors

Any characteristic that increases exposure to unopposed estrogen increases the risk for endometrial cancer (Table 2).2,48 Conversely, decreasing exposure to estrogen limits the risk. Unopposed estrogen therapy, obesity, anovulatory cycles and estrogen-secreting neoplasms all increase the amount of unopposed estrogen and thereby increase the risk for endometrial cancer. Smoking seems to decrease estrogen exposure, thereby decreasing the cancer risk, and oral contraceptive use increases progestin levels, thus providing protection.9 Tamoxifen (Nolvadex) therapy, often used in women with breast cancer, has an estrogenic effect on the female genital tract and, through this unopposed estrogen exposure, increases the risk for endometrial cancer.10 Physicians should be aware that endometrial ablation is not a treatment for endometrial hyperplasia or carcinoma, and a previous ablation does not protect against the development of endometrial disease.

TABLE 2

Risk Factors for Endometrial Cancer

Unopposed estrogen exposure

Median age at diagnosis: 59 years

Menstrual cycle irregularities, specifically menorrhagia and menometrorrhagia

Postmenopausal bleeding

Chronic anovulation

Nulliparity

Early menarche (before 12 years of age)

Late menopause (after 52 years of age)

Infertility

Tamoxifen (Nolvadex) use

Granulosa and thecal cell tumors

Ovarian dysfunction

Obesity

Diabetes mellitus

Arterial hypertension with or without atherosclerotic heart disease

History of breast or colon cancer


Information from references 2, and 4 through 8.

TABLE 2   Risk Factors for Endometrial Cancer

View Table

TABLE 2

Risk Factors for Endometrial Cancer

Unopposed estrogen exposure

Median age at diagnosis: 59 years

Menstrual cycle irregularities, specifically menorrhagia and menometrorrhagia

Postmenopausal bleeding

Chronic anovulation

Nulliparity

Early menarche (before 12 years of age)

Late menopause (after 52 years of age)

Infertility

Tamoxifen (Nolvadex) use

Granulosa and thecal cell tumors

Ovarian dysfunction

Obesity

Diabetes mellitus

Arterial hypertension with or without atherosclerotic heart disease

History of breast or colon cancer


Information from references 2, and 4 through 8.

HORMONE REPLACEMENT THERAPY

Unopposed estrogen treatment of menopause is associated with an eightfold increased incidence of endometrial cancer.11,12 The addition of progestin decreases this risk dramatically.12 For maximum endometrial protection, administration of medroxyprogesterone acetate (Provera), in a dosage of 10 mg daily, or norethindrone acetate (Aygestin), in a dosage of 2.5 mg daily, for a minimum of 12 to 14 days per month has been recommended.13 However, some physicians prescribe lower dosages, either 5.0 or 2.5 mg of medroxyprogesterone daily.

A 13-day “progestin challenge” course of either 10 mg of medroxyprogesterone or 2.5 to 5 mg of norethindrone given to post-menopausal women resulted in withdrawal bleeding and correlated with a high likelihood of endometrial pathology.13 In this study, it was found that low dosages may not provide maximal endometrial protection.13 However, the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial14 found no difference in the risk for endometrial disease between patients taking placebo and those taking estrogen with medroxyprogesterone, in a dosage of either 10 mg per day for 12 days or 2.5 mg per day continuously.

One possible explanation for these contradictions can be found in the patient groups studied. Many of the patients in one study had one or more risk factors for endometrial disease,13 whereas the PEPI trial involved a randomly selected cohort.14 These findings suggest that patients at high risk for endometrial disease should receive higher dosages of progestins than patients at low risk, a suggestion that is supported, in theory, by the pathophysiology. Further studies may be necessary for more definitive recommendations.

Screening

Population screening is not economically feasible; therefore, assessing the risk of individual patients is essential to reduce the morbidity and mortality of uterine cancer. By identifying women who are at high risk for endometrial neoplasia (Table 2), physicians can be selective about the use of endometrial sampling.

The Papanicolaou (Pap) test is not helpful in identifying women who are at increased risk for endometrial neoplasia. In one study, the presence of normal endometrial cells in post-menopausal women not on hormonal therapy was associated with a 19 percent risk for endometrial hyperplasia or carcinoma.15 Although a normal Pap smear does not indicate that a woman is at low risk for endometrial neoplasia, the presence of endometrial cells on a Pap smear in a postmenopausal woman who is not receiving hormonal therapy should be evaluated by endometrial biopsy.15

Clinical Signs and Symptoms

Ninety percent of patients with endometrial cancer have abnormal vaginal bleeding. This usually presents as menometrorrhagia in a perimenopausal woman or menstrual-like bleeding in a woman past menopause.2 Perimenopausal women relate a history of inter-menstrual bleeding, excessive bleeding lasting longer than seven days or an interval of less than 21 days between menses. Heavy, prolonged bleeding in patients known to be at risk for anovulatory cycles should prompt histologic evaluation of the endometrium.

Elderly women who have had many years of estrogen deficiency occasionally present with pelvic pain and are found to have retained blood in the uterine cavity (hematometra) related to cervical stenosis. These patients may require surgical intervention to obtain a specimen of the endometrium.

Although physicians should have a high index of suspicion for endometrial cancer in women who are obese, have diabetes and are past menopause, 35 percent of patients with endometrial cancer show no signs of obesity or hyperestrogenism.2 The findings on abdominal examination are usually normal, and the pelvic examination may show only evidence of mild vaginal bleeding. Any suspicious palpable lesions of the vulva, vagina or cervix should be carefully inspected and, if warranted, a biopsy specimen should be obtained to exclude metastatic disease or other causes of vaginal bleeding.

The physician should note particularly the size, contour, mobility and position of the uterus. These findings can be helpful in determining risks for complications with diagnostic testing, such as endometrial biopsy, and the possibility of metastatic or locally advanced disease. The adnexal examination is extremely important because endometrial cancer may be the result of a coexisting estrogen-secreting ovarian tumor such as a granulosa cell tumor.2

Diagnosis and Evaluation

Patients who report abnormal vaginal bleeding and have risk factors for endometrial cancer (Table 2) should have histologic evaluation of the endometrium. Premenopausal patients with amenorrhea for more than six to 12 months should be offered endometrial sampling, especially if they have risk factors associated with excessive estrogen exposure. Post-menopausal women with vaginal bleeding who either are not on hormonal replacement therapy or have been on therapy longer than six months should be evaluated by endometrial sampling.

DIAGNOSIS

Over the past decade, pathologists have defined the patterns of endometrial hyperplasia and atypia. Using small specimens, they can usually arrive at an accurate diagnosis. Most endometrial biopsy findings fall into one of four categories (Table 3).16 Based on current research, the presence of atypia indicates risk for progression to cancer.2 In several studies of women with endometrial hyperplasia, more than 80 percent of those without atypia responded to progestin therapy, compared with only 50 percent of those with atypia. Carcinoma developed in 25 percent of patients with atypia as opposed to less than 2 percent of those without atypia.46

TABLE 3

Four Major Types of Pathologic Findings on Endometrial Biopsy

Proliferative, secretory, benign or atrophic endometrium

Simple or complex (adenomatous) hyperplasia without atypia

Simple or complex (adenomatous) hyperplasia with atypia

Endometrial adenocarcinoma


Information from Jones MW, Kurman RJ. New ways of managing endometrial hyperplasia. Contemp Ob Gyn 1990;35:36–46.

TABLE 3   Four Major Types of Pathologic Findings on Endometrial Biopsy

View Table

TABLE 3

Four Major Types of Pathologic Findings on Endometrial Biopsy

Proliferative, secretory, benign or atrophic endometrium

Simple or complex (adenomatous) hyperplasia without atypia

Simple or complex (adenomatous) hyperplasia with atypia

Endometrial adenocarcinoma


Information from Jones MW, Kurman RJ. New ways of managing endometrial hyperplasia. Contemp Ob Gyn 1990;35:36–46.

ENDOMETRIAL SAMPLING

The gold standard for histologic evaluation of the endometrium has been dilatation and curettage (D&C). In-office endometrial sampling devices, however, have proved to be effective in screening the endometrium for disease without the inconvenience, cost or risk of an operating-room procedure. Numerous studies have found the results of office sampling to approach those of D&C, with an accuracy of 90 to 95 percent.1720

Several devices have been developed for in-office sampling of the endometrial lining. These include the Novak or Kevorkian curet, the Pipelle endometrial-suction curet and the Vabra aspirator (Table 4).2124

TABLE 4

Options for Evaluation of the Endometrium

Options Advantages Disadvantages Sensitivity (%) Specificity (%)

Pipelle suction curet

Cost effective, disposable; no anesthesia needed

Not reusable; small risk of perforation

Disease: 45

98

Cancer: 100

99

Vabra aspirator

Disposable; may require anesthesia

Possible perforation; equipment needed; noisy; not portable; expensive

83

Not available

Curet

Reusable; may require anesthesia

Rigid; possible perforation; equipment needed; patient discomfort

94

Not available

Transvaginal ultrasonography

Noninvasive; negative predictive value 99%; detects additional disease; little patient discomfort; safe

Expensive; not for screening; positive predictive value 9%

Asymptomatic patients: 90

48

Patients with bleeding: 82

80 [corrected]


Information from references 21 through 24.

TABLE 4   Options for Evaluation of the Endometrium

View Table

TABLE 4

Options for Evaluation of the Endometrium

Options Advantages Disadvantages Sensitivity (%) Specificity (%)

Pipelle suction curet

Cost effective, disposable; no anesthesia needed

Not reusable; small risk of perforation

Disease: 45

98

Cancer: 100

99

Vabra aspirator

Disposable; may require anesthesia

Possible perforation; equipment needed; noisy; not portable; expensive

83

Not available

Curet

Reusable; may require anesthesia

Rigid; possible perforation; equipment needed; patient discomfort

94

Not available

Transvaginal ultrasonography

Noninvasive; negative predictive value 99%; detects additional disease; little patient discomfort; safe

Expensive; not for screening; positive predictive value 9%

Asymptomatic patients: 90

48

Patients with bleeding: 82

80 [corrected]


Information from references 21 through 24.

Before having an in-office biopsy, the patient should take a preoperative dose of a non-steroidal anti-inflammatory drug (NSAID). With the patient in the lithotomy position, a speculum is inserted in the vaginal canal. The cervix should be clearly visualized and cleansed with a small amount of an antiseptic solution. Many physicians generally perform the endometrial biopsy without anesthesia, and most patients are able to tolerate this well. However, use of a paracervical block, as well as an NSAID, greatly improves patient tolerance and compliance.

After 1 mL of a local anesthetic is infused into the anterior lip of the cervix, a tenaculum can be placed. The paracervical block is then performed using 1 or 2 percent lidocaine (Xylocaine) without epinephrine (Figure 1). When the block is achieved, patients with slight cervical stenosis can be dilated with lacrimal dilators without causing great discomfort. This is followed by the use of a uterine sound to determine the direction and measure the length of the uterine cavity.

Paracervical Block

FIGURE 1.

Diagram of paracervical block.

View Large

Paracervical Block


FIGURE 1.

Diagram of paracervical block.

Paracervical Block


FIGURE 1.

Diagram of paracervical block.

The cannula is then placed in the uterus and placement is confirmed with the help of the centimeter markings along the cannula. Light downward traction on the tenaculum can be used to straighten the cervical canal and allow for easier passage of the sampling device. The inner sleeve is then pulled back while the cannula is held within the cavity. This generates a vacuum in the cannula that can be used to collect endometrial tissue for diagnosis. Moving the cannula in and out of the cavity no more than 2 to 3 cm with each stroke while turning the cannula clockwise or counterclockwise is helpful in obtaining specimens from the entire cavity.

Once material is seen in the top of the cannula, the instrument can be removed. The specimen is then placed in formalin and sent to the laboratory for histologic diagnosis. If no tissue is obtained, a second cannula can be used, or a small Novak curet can be placed in the uterine cavity and a gentle curettage can be performed. Some patients have atrophic endometrium, and little or no tissue will be obtained. In these patients, close observation can be maintained, or a D&C can be performed with general or spinal anesthesia.

OTHER SCREENING TECHNIQUES

Ultrasonographic measurement of endometrial thickness has been suggested as a screening technique to obtain an image of the endometrial lining and predict the likelihood of disease based on its thickness. However, current information (Table 4) does not support routine use of this approach. Numerous studies measuring endometrial thickness with the use of transvaginal ultrasonography have indicated that an endometrial thickness of less than 5 mm is rarely associated with carcinoma.2,25,26 In the Nordic trial,26 the largest study to date, a cutoff of less than 5 mm was associated with 96 percent sensitivity, 68 percent specificity and an accuracy of 78 percent for detecting histologically abnormal endometrium in patients with postmenopausal bleeding.

In other studies of transvaginal ultrasonography,22,27 investigators concluded that the data support its use for surveillance of women on tamoxifen therapy and those with post-menopausal bleeding and endometrial cells seen on cervical cytologic examination.22,27

Transvaginal ultrasonography may be helpful in determining which patients should have a biopsy (endometrial thickness greater than 4 mm) and in detecting other pelvic abnormalities in women reporting abnormal uterine bleeding.

Sonohysterography is now being used to look at the features of the endometrial lining, in particular to distinguish thickness from polyps and leiomyomas, which are the common uterine abnormalities missed by endometrial biopsy.25

Inpatient or outpatient hysteroscopy, which is the direct inspection of the endometrium, has been used to evaluate cases of abnormal uterine bleeding. Its many advantages over endometrial biopsy, transvaginal ultrasonography, sonohysterography and D&C include direct visualization of the endometrium, which provides the opportunity to obtain a biopsy specimen and remove lesions, especially polyps and leiomyomas. Its disadvantages include surgical risks, which are similar to those of D&C, and the additional concerns of cost and the possible spread of malignant cells into the peritoneal cavity.4

Treatment

The treatment of endometrial cancer is usually surgical, such as total abdominal hysterectomy, bilateral salpingo-oophorectomy and evaluation for metastatic disease, which may include pelvic or para-aortic lymphadenectomy, peritoneal cytologic examination and peritoneal biopsies. The extent of the surgical procedure is based on the stage of disease (Table 5),28 which can be determined only at the time of the operation.

TABLE 5

Staging for Carcinoma of the Corpus Uteri

Stage* Description

IA (G1, G2, G3)

Tumor limited to endometrium

IB (G1, G2, G3)

Invasion of less than one half of the myometrium

IC (G1, G2, G3)

Invasion of more than one half of the myometrium

IIA (G1, G2, G3)

Endocervical gland involvement

IIB (G1, G2, G3)

Cervical stromal involvement

IIIA (G1, G2, G3)

Invasion of serosa and/or adnexa and/or positive peritoneal cytologic results

IIIB (G1, G2, G3)

Metastases to vagina

IIIC (G1, G2, G3)

Metastases to pelvic and/or para-aortic lymph nodes

IVA (G1, G2, G3)

Invasion of bladder and/or bowel mucosa

IVB

Distant metastases including intra-abdominal and/or inguinal lymph nodes


*—Carcinoma of the corpus is graded (G) according to the degree of histologic differentiation: G1 = 5 percent or less of a solid growth pattern; G2 = 6 to 50 percent of a solid growth pattern; G3 = more than 50 percent of a solid growth pattern.

Adapted with permission from Elsevier Science, from International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 1989;28:189–90.

TABLE 5   Staging for Carcinoma of the Corpus Uteri

View Table

TABLE 5

Staging for Carcinoma of the Corpus Uteri

Stage* Description

IA (G1, G2, G3)

Tumor limited to endometrium

IB (G1, G2, G3)

Invasion of less than one half of the myometrium

IC (G1, G2, G3)

Invasion of more than one half of the myometrium

IIA (G1, G2, G3)

Endocervical gland involvement

IIB (G1, G2, G3)

Cervical stromal involvement

IIIA (G1, G2, G3)

Invasion of serosa and/or adnexa and/or positive peritoneal cytologic results

IIIB (G1, G2, G3)

Metastases to vagina

IIIC (G1, G2, G3)

Metastases to pelvic and/or para-aortic lymph nodes

IVA (G1, G2, G3)

Invasion of bladder and/or bowel mucosa

IVB

Distant metastases including intra-abdominal and/or inguinal lymph nodes


*—Carcinoma of the corpus is graded (G) according to the degree of histologic differentiation: G1 = 5 percent or less of a solid growth pattern; G2 = 6 to 50 percent of a solid growth pattern; G3 = more than 50 percent of a solid growth pattern.

Adapted with permission from Elsevier Science, from International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 1989;28:189–90.

For most patients whose cancers have progressed beyond stage IB grade 2, postoperative radiation therapy is recommended.2 This may include simple vaginal vault irradiation or external pelvic irradiation with or without extended abdominal irradiation, based on the extent of disease.2

Because tumor response to cytotoxic chemotherapy has been poor, chemotherapy is used only for palliation. Progestin has also been used to treat recurrent endometrial cancer, but the response rates have been poor.2931

Endometrial hyperplasia with atypia should be treated with hysterectomy except in extraordinary cases. Progestin treatment is a possibility in women younger than 40 years of age who refuse hysterectomy or who wish to retain their childbearing potential, but an endometrial biopsy should be performed every three months.16 Investigators have reported that treatment of atypical hyperplasia and well-differentiated endometrial cancer with progestins in women younger than 40 years of age resulted in complete regression of disease in 94 percent and 75 percent, respectively.32 This was a group of women who wished to preserve their fertility, and medical therapy may not be justified in patients for whom fertility is not an issue. When women who choose medical therapy complete childbearing, reevaluation of the endometrium should be performed, and hysterectomy should be recommended if hyperplasia with atypia is identified.

Patients found to have hyperplasia without atypia should be treated with progestins and have an endometrial biopsy every three to six months.16 Hysterectomy is an option for those who are unwilling to take progestins or who have persistent hyperplasia despite progestin treatment (Figure 2).2,26 The ideal type and amount of progestin necessary to protect the endometrium is still unknown, and no data define the optimal duration of treatment.33 If risk factors remain unchanged, the clinician should consider continuing progestin treatment for an additional 12 months after a normal biopsy, with annual endometrial biopsies performed as follow-up. Many clinicians still recommend that women older than 50 years consider hysterectomy as a definitive treatment.

Management of Hyperplasia Without Atypia

FIGURE 2.

Algorithm for the management of hyperplasia without atypia.

Adapted from Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326, with information from Karlsson B, Granberg S, Wikland M, Ylostalto P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488–94.

View Large

Management of Hyperplasia Without Atypia


FIGURE 2.

Algorithm for the management of hyperplasia without atypia.

Adapted from Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326, with information from Karlsson B, Granberg S, Wikland M, Ylostalto P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488–94.

Management of Hyperplasia Without Atypia


FIGURE 2.

Algorithm for the management of hyperplasia without atypia.

Adapted from Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326, with information from Karlsson B, Granberg S, Wikland M, Ylostalto P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol 1995;172:1488–94.

The Authors

TIMOTHY P. CANAVAN, M.D., is director of obstetrics and gynecology, associate director of the family practice residency program and physician analyst for the Department of Information Systems at Lancaster (Pa.) General Hospital. In addition, he is clinical assistant professor of obstetrics and gynecology at Temple University School of Medicine, Philadelphia. Dr. Canavan received his medical degree from the State University of New York Health Science Center at Brooklyn and completed a residency in obstetrics and gynecology at Staten Island University Hospital in New York City.

NIPA R. DOSHI, M.D., is a third-year resident in family practice at Lancaster General Hospital, where she serves as the residency program's fellow in faculty development. Dr. Doshi graduated from Allegheny University of the Health Sciences Hahnemann School of Medicine in Philadelphia. Her areas of interest include women's health and obstetrics.

Address correspondence to Timothy P. Canavan, M.D., Family Practice Residency, Lancaster General Hospital, 555 N. Duke St., Lancaster, PA 17604. Reprints are not available from the authors.

REFERENCES

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1997. CA Cancer J Clin. 1997;47:5–27[Published erratum in CA Cancer J Clin 1997;47:68]

2. Berek JS, Hacker NF, eds. Practical gynecologic oncology. 2d ed. Baltimore: Williams & Wilkins, 1994:285–326.

3. Barakat RR. Contemporary issues in the management of endometrial cancer. CA Cancer J Clin. 1998;48:299–314.

4. Ferenczy A, Gelfand MM, Tzipris F. The cytodynamics of endometrial hyperplasia and carcinoma: a review. Ann Pathol. 1983;3:189–202.

5. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–12.

6. Ferenczy RJ, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126–31.

7. Kurman RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 3d ed. New York: Springer-Verlag, 1987:352.

8. Poma PA. Endometrial cancer: broadening the focus on prevention. Female Patient. 1997;22:39–43.

9. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 1991;41:1–16.

10. Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol. 1996;39:629–40.

11. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294:1262–7.

12. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–13.

13. Gambrell RD Jr. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol. 1997;177:1196–207.

14. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;275:370–5.

15. Ng AB, Reagan JW, Hawliczek S, Wentz BW. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors. Acta Cytol. 1974;18:356–61.

16. Jones MW, Kurman RJ. New ways of managing endometrial hyperplasia. Contemp Ob Gyn. 1990;35:36–46.

17. American College of Obstetricians and Gynecologists. Carcinoma of the endometrium. Technical bulletin no. 162. Washington, D.C.: American College of Obstetricians and Gynecologists, 1991.

18. Cohen CJ, Gusberg SB, Koffler D. Histologic screening for endometrial cancer. Gynecol Oncol. 1974;2:279–86.

19. Creasman WT, Weed JC Jr. Screening techniques in endometrial cancer. Cancer. 1976;38(1 suppl):436–40.

20. Walters D, Robinson D, Park RC, Patow WE. Diagnostic outpatient aspiration curettage. Obstet Gynecol. 1975;46:160–4.

21. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease: the Post-menopausal Estrogen/Progestin Interventions Trial. N Engl J Med. 1997;337:1792–8.

22. Van den Bosch T, Vandendael A, Van Schoubroeck D, Wranz PA, Lombard CJ. Combining vaginal ultrasonography and office endometrial sampling in the diagnosis of endometrial disease in postmenopausal women. Obstet Gynecol. 1995;85:349–52.

23. Rodriguez GC, Yaqub N, King ME. A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol. 1993;168(pt 1):55–9.

24. Stovall TG, Ling FW, Morgan PL. A prospective, randomized comparison of the Pipelle endometrial sampling device with the Novak curette. Am J Obstet Gynecol. 1991;165(pt 1):1287–90.

25. Blumenfeld ML, Turner LP. Role of transvaginal sonography in the evaluation of endometrial hyperplasia and cancer. Clin Obstet Gynecol. 1996;39:641–55.

26. Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with post-menopausal bleeding: a Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488–94.

27. Lerner JP, Timor-Tritsch IE, Monteagudo A. Use of transvaginal sonography in the evaluation of endometrial hyperplasia and carcinoma. Obstet Gynecol Surv. 1996;51:718–25.

28. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet. 1989;28:189–90.

29. Podratz KC, O'Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985;66:106–10.

30. Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer. 1980;45:268–72.

31. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol. 1991;9:1071–88.

32. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–40.

33. McGonigle KF. How progestins reduce endometrial cancer risk in ERT users. Contemp Ob Gyn. 1997;42:96–108.


Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article